

Amendment

In the Claims

91

15. (amended) A composition comprising a compound according to claim 1, and a pharmaceutical carrier.

92

17. (amended) A pharmaceutical composition for inhibiting the binding of somatostatin to a somatostatin receptor of type 2, comprising an effective amount of a compound according to claim 1, and a pharmaceutical carrier.

Please cancel Claim 16 and Claim 21 without prejudice.

Marked up Copies of Claims

15. (marked up) A [pharmaceutical] composition [for increasing growth hormone secretion in a mammal,] comprising an effective amount of a compound according to claim 1, and a pharmaceutical carrier.

17. (marked up) A pharmaceutical composition for inhibiting the binding of somatostatin to a somatostatin receptor of type 2 [an sst2] receptor, comprising an effective amount of a compound according to claim 1, and a pharmaceutical carrier.

Remarks

The Examiner has noted the presence of various chemical depictions in the Specification wherein, preferably, a hydrogen atom should be shown attached to a nitrogen atom which participates in an amide linkage. Applicants will correct all such instances, along with similar occurrences in the claims, as soon as the Examiner indicates the scope of claim amendments that are needed (see Preliminary Remarks above). It is believed this will result in one clean set of amendments as opposed to multiple submissions.

In regard of the section 112 (second paragraph) rejections, Claim 17 has been amended to address the rejection. The Examiner has correctly pointed out that the subject matter of claim